Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for LX9851 in Obesity, Cardiovascular disease . The expected timing is based on the latest available company guidance and may change.
3/28/25- Exclusive licensing agreement with Novo Nordisk. 11/06/25:- All IND-enabling studies completed and submitted to NVO; NVO is preparing an IND filing. 3/05/26:- IND-enabling work completed 2025; NVO paid $10M milestone Feb 2026 with up to $20M more potential. 03/23/26:- Phase 1 initiated; initial dosing triggered $10M milestone. Phase 1 completion expected Q1 2027. 05/07/26:- Novo Nordisk Phase 1 program completion still expected Q1 2027; potential $10M third milestone may be earned 2026. 08/06/26:- LX9851 Ph1 ongoing. Completion expected Q1 2027. Third milestone possible later 2026.
Verification
Confirm timing and program details against the company announcement or filing.